Loading company
Loading
Latest annual · FY2024
Millions- Total revenues
- 1
- Operating income
- (139)
- Net income
- (131)
- Free cash flow
- (93)
Latest quarter · Q3 FY2025
Millions- Free cash flow
- (28)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2021 to FY2024
- -48.9%
- Revenue, 5 yearsFY2019 to FY2024
- +32.0%
- Net income, 5 yearsFY2019 to FY2024
- n/m
Adverum Biotechnologies, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Revenue | $1 million | $3.6 million | -72.2% | 10-K 2025-04-15 · proof |
| Operating income | -$139.2 million | -$128.9 million | 10-K 2025-04-15 · proof | |
| Net income | -$130.9 million | -$122.1 million | 10-K 2025-04-15 · proof | |
| Cash from operating activities | -$92.5 million | -$90.9 million | 10-K 2025-04-15 · proof | |
| Free cash flow | -$92.9 million | -$91.7 million | 10-K 2025-04-15 · proof | |
| Total assets | $179.8 million | $155.8 million | +15.5% | 10-K 2025-04-15 · proof |
| Total liabilities | $109.1 million | $88.5 million | +23.2% | 10-K 2025-04-15 · proof |
| Cash and cash equivalents | $60.7 million | $75 million | -19.1% | 10-K 2025-04-15 · proof |
- What was Adverum Biotechnologies, Inc.'s revenue in fiscal 2024?
- Adverum Biotechnologies, Inc. reported revenue of $1 million for fiscal 2024 (the year ended Dec 31, 2024), against $3.6 million the year before (-72.2%). Source: the 10-K filed with the SEC on Apr 15, 2025. SEC
- What was Adverum Biotechnologies, Inc.'s operating income in fiscal 2024?
- Adverum Biotechnologies, Inc. reported operating income of -$139.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -$128.9 million the year before. Source: the 10-K filed with the SEC on Apr 15, 2025. SEC
- What was Adverum Biotechnologies, Inc.'s net income in fiscal 2024?
- Adverum Biotechnologies, Inc. reported net income of -$130.9 million for fiscal 2024 (the year ended Dec 31, 2024), against -$122.1 million the year before. Source: the 10-K filed with the SEC on Apr 15, 2025. SEC
- What was Adverum Biotechnologies, Inc.'s cash from operating activities in fiscal 2024?
- Adverum Biotechnologies, Inc. reported cash from operating activities of -$92.5 million for fiscal 2024 (the year ended Dec 31, 2024), against -$90.9 million the year before. Source: the 10-K filed with the SEC on Apr 15, 2025. SEC
- What was Adverum Biotechnologies, Inc.'s free cash flow in fiscal 2024?
- Adverum Biotechnologies, Inc. reported free cash flow of -$92.9 million for fiscal 2024 (the year ended Dec 31, 2024), against -$91.7 million the year before. Source: the 10-K filed with the SEC on Apr 15, 2025. SEC
- What are Adverum Biotechnologies, Inc.'s total assets?
- As of Dec 31, 2024, Adverum Biotechnologies, Inc. reported total assets of $179.8 million, against $155.8 million a year earlier (+15.5%). Source: the 10-K filed with the SEC on Apr 15, 2025. SEC
- What are Adverum Biotechnologies, Inc.'s total liabilities?
- As of Dec 31, 2024, Adverum Biotechnologies, Inc. reported total liabilities of $109.1 million, against $88.5 million a year earlier (+23.2%). Source: the 10-K filed with the SEC on Apr 15, 2025. SEC
- What are Adverum Biotechnologies, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Adverum Biotechnologies, Inc. reported cash and cash equivalents of $60.7 million, against $75 million a year earlier (-19.1%). Source: the 10-K filed with the SEC on Apr 15, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1501756&period_type=annual&limit=5"Information only, not investment advice.